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EndocytosisUrsodeoxycholic acid (UDCA) has been shown to prevent colon tumorigenesis in animal models and in
humans. In vitro work indicates that this bile acid can suppress cell growth and mitogenic signaling
suggesting that UDCA may be an anti-proliferative agent. However, the mechanism by which UDCA functions
is unclear. Previously we showed that bile acids may alter cellular signaling by acting at the plasma
membrane. Here we utilized EGFR as a model membrane receptor and examined the effects that UDCA has
on its functioning. We found that UDCA promoted an interaction between EGFR and caveolin-1 and this
interaction enhanced UDCA-mediated suppression of MAP kinase activity and cell growth. Importantly,
UDCA treatment led to recruitment of the ubiquitin ligase, c-Cbl, to the membrane, ubiquitination of EGFR,
and increased receptor degradation. Moreover, suppression of c-Cbl activity abrogated UDCA's growth
suppression activities suggesting that receptor ubiquitination plays an important role in UDCA's biological
activities. Taken together these results suggest that UDCA may act to suppress cell growth by inhibiting the
mitogenic activity of receptor tyrosine kinases such as EGFR through increased receptor degradation.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Bile acids are polar derivatives of cholesterol that are excreted into
the digestive tract where they aid in the emulsiﬁcation and absorption
of dietary fats [1]. Although bile acids have a clear role in digestion they
have also been implicated by epidemiological studies as modiﬁers of
colon cancer etiologywith deoxycholic acid (DCA) being identiﬁed as a
key culprit in the promotion of colon tumorigenesis by high fat diets
[2–4]. However, recent evidence suggests that another bile acid,
ursodeoxycholic acid (UDCA) has chemopreventive properties in both
animal models [5–7] and in humans [8] suggesting that these agents
have distinctly different effects on the colonic epithelium. Consistent
with this we have shown that DCA is cytotoxic and induces apoptosis
on cells in culture, whereas UDCA induces senescence and growth
suppression [9]. Surprisingly DCA and UDCA have nearly identical
chemical structures differing only in the position of one hydroxyl
group which can be located on either the C-7 or C-11 positions of the
cholesterol nucleus in DCA or UDCA respectively. The mechanism by
which these two structurally related bile acids exhibit such opposing
biological effects remains unclear.
In previous studies we proposed that bile acids may exert their
biological effects by activating intracellular signaling and that this activity
is initiatedat thecell surface. Early studiesofDCAshowedthat thisbile acid
activated protein kinase C as well as the MAP kinase signaling pathwayrtinez).
ll rights reserved.[10] and that this activity was induced through the ligand-independent
activation of EGFR [10,11] which led to activation of the AP-1 transcription
factor [12]. Importantly, DCA's ability to stimulate intracellular signaling
was related to its hydrophobicity and ability to alter the composition of the
cell membrane [13,14] suggesting that this structure was the origin of bile
acid-induced intracellular signaling. In contrast, UDCA was found to
suppress DCA-induced signaling [15,16] but, surprisingly, was also shown
to accumulate in the plasma membrane [17]. These observations
supported the idea that both of these bile acids might be exerting their
biological effects by altering the plasma membrane.
We previously showed that plasmamembrane alterations caused by
DCA resulted in the phosphorylation of membrane-associated caveolin-
1 [13]. Caveolin-1 is a structural protein found in caveolae lipid rafts in
theplasmamembrane [18]which serve as signalingplatforms for awide
variety of membrane signaling pathways including the EGF receptor
which stimulates MAP kinase signaling. Importantly, loss or disruption
of caveolae can result in aberrant signaling [19]. Caveolin-1 is a key
structural component of caveolae, but it also is thought to regulate
receptor activity by binding with receptors and suppressing their
activity. Loss of caveolin-1 facilitates development of tumors in mice
which suggests that caveolin-1 may be a tumor suppressor [20,21].
In these studies we used EGFR as a model system to examine the
effects that UDCA and DCA have on receptor tyrosine kinases and
tested whether the biological activities of these two bile acids was
affected by the presence or absence of caveolin-1. We show that UDCA
suppresses EGFR signaling by promoting endocytosis and degradation
of the receptor and that this is facilitated by the presence of caveolin-1.
Fig. 1. Caveolin-1 enhances suppression of growth and MAP kinase signaling by UDCA.
(A) HT29 and HT29-cav-1 cells were plated onto 10 cm plates and grown in the
presence of 1mM IPTG for the number of hours indicated. The cells were then harvested
and cell lysates examined by immunoblotting for the caveolin-1 and beta actin. (B)
HT29 and HT29-Cav-1 cells were plated onto 60 mm plates and grown in the presence
of 1 mM IPTG for 24 h prior to the addition of 250 μMUDCA. Cells were trypsinized from
the plates at regular intervals and counted. Graphs represent the total number of cells/
plate expressed as a percentage of the initial cell count. The experiment was performed
in triplicate and repeated twice. Error bars represent standard error. (C) HT29 and
HT29-cav-1 cells were grown on 60 mm plates and caveolin expression induced as
described in panel A. Subsequently, cells were either not further treated or incubated
with 500 μM DCA for 16 h. Cells were then harvested by trypsinization and the fraction
of viable, apoptotic, and necrotic cells determined by ﬂuorescent microscopy after
staining with acridine orange/ethidium bromide [9]. The bars depict the average from
three experiments. Error bars show standard deviation.
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on colon tumor etiology is discussed.
2. Materials and methods
2.1. Bile acids and antibodies
DCA was obtained from Sigma (St. Louis, MO) and UDCA was
obtained from Calbiochem (La Jolla, CA). Bile acids weremaintained in
stock solutions of 100 mM, dissolved in double-distilled water. The
caveolin-1, c-CBL, EGFR, and ﬂotillin-2 antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-MAP kinase
activated (diphosphorylated ERK-1 and 2) antibody was purchased
from Sigma (St. Louis, MO). The ubiquitin and total ERK 1 and 2
antibodies were obtained from Upstate Biotechnology (Lake Placid,
NY). The mannose-6-phosphate receptor antibody was purchased
from Abcam (Cambridge, MA). The ﬂuorescent probes, Alexa Fluor
594 and 488 were purchased from Molecular Probes (Eugene, OR).
Mouse and rabbit secondary antibodies were purchased from
Kirkegaard and Perry Laboratories (Gaithersburg, MD).
2.2. Cell lines
The HT-29 cell lines, derived from human colorectal adenocarci-
noma, were obtained from the American Tissue Type Culture
Collection (Manassas, VA). The stably transfected cell line HT29-cav-
1, was generously provided by Dr. Emanuela Felley-Bosco (Institute of
Biochemistry, University of Lausanne, Lausanne, Switzerland) and has
been described previously [20]. All cell lines were grown at 37 °C and
in humidiﬁed, 5% CO2 incubators. Cells were maintained in Dulbeccos
modiﬁed Eagle's medium (DMEM) (Gibco BRL, Gaithersburg, MD)
supplemented with 10% (v/v) fetal bovine complex (Gemini Biopro-
ducts, Sacramento, CA.), 4 mM sodium pyruvate, 100 U/ml penicillin/
streptomycin, and 100 μM non-essential amino acids.
2.3. Analysis of proliferation — growth curves
Primary cultures of HT29 and HT29-cav-1 cells were seeded in
60 mm dishes at a density of 50,000 cells/dish. Cell number was
counted with the Bright Line Counting Chamber (Hausser Scientiﬁc,
PA) every 6 h for 3 days of incubation at 37 °C. Each point represents
the total number of cells per plate expressed as a percentage of initial
cell count. The experiment was performed in triplicate and repeated
twice. Error bars depict variation between experiments.
2.4. Sucrose gradient fractionation of cellular membranes
Total cell membranes were fractionated according to the method of
Song et al. [22] with some modiﬁcations. Brieﬂy, cells were cultivated in
10 cm dishes, washed twice with PBS and scraped into 2 ml of 500 mM
sodium carbonate (pH 11.0). The cell suspensions were homogenized on
icewith loose-ﬁtting Dounce Homogenizer (10 strokes), and subjected to
sonication using an ultrasonicator (three 10 second bursts). The
homogenate was adjusted to 45% sucrose by adding an equal volume of
90% sucrose prepared in MBS (25 mM MES, pH 6.5, 150 mM NaCl) and
placedat thebottomof ultraclear centrifuge tubes (Beckman Instruments,
Palo Alto, CA). A 5–35% discontinuous sucrose gradientwas layered above
using equal volumes of 35% and 5% sucrose over the cell homogenate
layer. The gradients were centrifuged to equilibrium by centrifugation at
160,000 ×g for 18 h in a SW41 rotor at 4 °C. Twelve 1 ml fractions were
collected from top to bottom, stored at 4 °C for later analysis.
2.5. Immunoﬂuorescence
Cells were seeded on coverslips in 12 well dishes and grown until
60% conﬂuent and then treated accordingly for each experiment. The
Fig. 2. Caveolin-1 facilitates suppression of MAP kinase signaling by UDCA. (inset) HT29
and HT29-Cav-1 cells were plated onto 10 cm dishes and caveolin-1 induced as described in
Fig.1. The cells were then incubated for 18 h in serum free media and subsequently exposed
to 0, 50,100, or 200 ng/ml EGF for 15 min. Cells were analyzed for the presence of total
ERK1/2 and phosphorylated ERK1/2 by immunoblotting and the quantity of phosphory-
lated ERK1/2 determined using Scion Image. The values graphed depict the extent of ERK
phosphorylation in HT29 (solid circles) and HT29-cav-1 (open circles) cells exposed to
increasing concentrations of EGF. These experiments served as controls for the following
studies. (Large graph) HT29 (solid circles) and HT29-Cav-1 (open circles) cells were grown
on 60 mm plates and caveolin-1 expression induced as described above, however, in
addition both cell lines were preincubated with 250 μM UDCA for 16 h. Subsequently, the
cells were incubated with the same concentrations of EGF as above and the extent of ERK1/
2 phosphorylation determined by immunoblotting. Band densities were quantitated using
Scion Image. The values graphed depict the change in activation of ERK by EGF in UDCA
pre-treated HT29 and HT29-cav1 cells normalized relative to cells not pre-treated with
UDCA (inset). The experiment was repeated twice. Error bars depict standard deviation.
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temperature, washed twicewith cold PBS, and permeabilized with 0.2%
TritonX-100 for 10min. Thiswas followedwith 3washeswith PBS and 2Fig. 3. UDCA induces internalization of EGFR and association with caveolin-1. (A) Caveolin
Subsequently cells were either not further treated (CTR), treated with 100 ng/ml EGF (+EGF
stained with anti-EGFR as described in Materials and methods. Confocal images of each trea
shown. (B) Caveolin-1 expressionwas induced in HT29-cav-1 cells as previously described an
or incubated with 250 μMUDCA (UDCA) or 250 μMDCA (DCA) for 18 h. Surface proteins were
the recovered proteins separated by SDS-PAGE electrophoresis and probed for the presence o
probed for EGFR using an anti-EGFR antibody. The experiment was repeated three times. Ty
described and the cells either not further treated (CTR), incubated with EGF for 15 min, or in
(W) or membrane preparations (M) were prepared and EGFR immunoprecipitated with an
presence of caveolin-1 using an anti-caveolin-1 antibody and for EGFR using an anti-EGFR awashes with the blocking reagent, 5% BSA in PBS. Coverslips were then
incubated for 1 h with primary antibodies (dilutions ranged from 1:100
to 1:500) at 32 °C. Subsequently the cells werewashed 3 timeswith PBS
and twice with 5% BSA followed by incubation with ﬂuorescence-
conjugated secondary antibodies at room temperature for 1 h. After
incubation, cells were washed with cold PBS, incubated with DAPI for
2 min, and washed 2 more times with PBS. Finally coverslips were
mounted with VECTASHIELD Mounting Medium (Vector Laboratories,
Burlingame, CA) and observed using a NIKON microscope and images
collected using Metamorph software.
2.6. Pulse chase analysis
Cells were grown to 70% conﬂuence and treated with bile acids
overnight. Cells were washed twice with pre-warmed phosphate
buffered saline, and incubated in L-cysteine and L-methionine-free
DMEM (Invitrogen) supplemented with 5% dialyzed fetal bovine
serum for 1 h. Cells were labeled with 150 μCi/ml L-[35S] methionine
(PerkinElmer, Waltham, MA) for 2 h, washed 3 times in pre-warmed
phosphate buffered saline, and chased in complete DMEM medium
containing 2 mM (unlabeled) L-methionine and L-cysteine, and 30 μg/
ml cyclohexamide (Sigma) for 0.5, 1, 1.5, and 3 h. Cells were lysed in
radioimmune precipitation buffer (150 mMNaCl, 50 mM Tris base, pH
7.2, 1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 0.5% aprotinin,
12.5 μg/ml leupeptin, 1 mM sodium vanadate), and immunoprecipi-
tated with anti-EGFR antibody, resolved by 7.5% SDS-PAGE. Gels were
ﬁxed, dried and autoradiographed to detect [35S] methionine-labeled
protein bands. For quantitation of EGFR bands, densities of the bands
were scanned with Molecular Dynamics PhosphorImager and quanti-
ﬁed with Image Quant software.
2.7. Stable transfection of expression vector and siRNA transfection
C381A-c-Cbl ring ﬁnger mutant in the expression vector pcDNA3
was a generous gift from Dr. Yosef Yarden (Department of Biological-1 was induced in HT29-cav-1 cells as previously described and then serum-starved.
) for 15min or incubatedwith 250 μMUDCA (UDCA) for 60min. The cells were ﬁxed and
tment group are depicted. The experiment was repeated three times. Typical results are
d the cells either not further treated (CTR), treated with 100 ng/ml EGF (EGF) for 15min
then biotinylated. EGFRwas then immunoprecipitated with an anti-EGFR antibody and
f biotin using horseradish-peroxidase-labeled streptavidin. Subsequently the ﬁlter was
pical results are shown. (C) Caveolin-1 was induced in HT29-cav-1 cells as previously
cubated with 250 μM DCA (DCA) or 250 μMUDCA (UDCA) for 18 h. Whole cells extracts
anti-EGFR antibody. Protein samples were separated by SDS-PAGE and probed for the
ntibody. The experiments were repeated three times. Typical results are shown.
Fig. 4. UDCA causes internalized EGFR to associate with late endosomes. HT29 and
HT29-cav-1 cells were grown on coverslips and incubated with 1 mM IPTG for 24 h. The
cells were serum-starved and then either left untreated (CTR) or incubatedwith 250 μM
UDCA or 250 μM DCA for 18 h. The cells were ﬁxed and co-stained for EGF receptor
(EGFR, red) and mannose-6-phosphate receptor (M6P-R, green). Merged images are
shown on the right (MERGE). White arrows point to endosomes that show
colocalization of both M6P and EGFR. The experiment was repeated three times and
images depict typical results.
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been described previously [23]. pcDNA3-HA-c-cbl and a pCMV-Tag2
empty vector were simultaneously transformed and subsequently
transfected into HT-29-cav-1 cells using LipoTAXI Mammalian
transfection kit (Stratagene, La Jolla, CA) according to the manufac-
turer's instruction manual. Stably transfected clones were selected in
the presence of 600 μg/ml G418, and individual clones expanded into
stable colonies.
3. Results
3.1. UDCA-induced growth suppression is enhanced in the presence
of caveolin-1
We previously showed that bile acids cause membrane perturba-
tions which led to activation of mitogenic signaling [12,17]. It hasbeen reported that signal transduction pathways involved in cell
proliferation are regulated at least in part through the caveolae
membrane domains [24]. Hence, we examined the effect that the
absence or presence of cav-1 had on UDCA suppression of cell
proliferation. To examine this we utilized HT29 cells which do not
express caveolin-1 and HT29-cav-1 cells which are transfected with
an inducible vector which drives expression of caveolin-1 in response
to IPTG (Fig. 1A). In all experiments the cells were incubated with
1 mM IPTG for 24 h prior to initiation of the experiment to induce
caveolin-1 in the HT29-cav-1 cells. As expected incubating HT29 cells
with UDCA caused a signiﬁcant suppression of cell growth when
compared with the untreated controls (p=0.0001). Importantly,
UDCA-induced growth suppression was signiﬁcantly enhanced in
caveolin-1 expressing cells when compared to UDCA-treated HT29
cells (p=0.0001; Fig. 1B). Indeed, the presence of caveolin-1
combined with UDCA treatment completely eliminated cell prolif-
eration. No signiﬁcant difference in growth between HT29 cells and
HT29-cav1 cells was observed. In contrast, the cytotoxic effects of
DCA were reduced in the presence of caveolin (Fig. 1C). DCA-induced
apoptosis approached 50% in HT29 cells. However under the same
conditions DCA-induced apoptosis in HT29-cav1 cells was only ∼20%
indicating that the presence of caveolin suppressed the cytotoxic
effects of this bile acid. Hence, it appears that caveolin has opposing
effects on the activity of these two bile acids. It enhanced the growth
suppressing activity of UDCA, but suppressed DCA-induced apopto-
sis. Importantly, caveolin-1 had no effect on its own on either cell
growth or cell death.
Since we previously showed that UDCA suppressed DCA-induced
EGFR signaling [16] we asked whether UDCA could suppress EGF-
induced signaling and whether the presence or absence of caveolin
had any effect on this. As expected we found that increasing
concentrations of EGF resulted in a dose-dependent increase in
ERK1/2 activation in HT29 and HT29-cav-1 cells and the magnitude of
ERK activation was similar for the two cell lines (Fig. 2, inset).
However, when the cells were pre-treated with UDCA, induction of
MAP kinase activity by EGF was reduced and this effect was enhanced
in the HT29-cav-1 cells (Fig. 2). These results reafﬁrm the observation
that UDCA can suppress MAP kinase signaling and that this effect is
enhanced in the presence of caveolin.
3.2. UDCA induces endocytosis, ubiquitination and degradation of EGFR
Attenuation of receptor signaling is normally accomplished by
receptor internalization followed by ubiquitination and degradation
[25]. Since UDCA could suppress receptor signaling we examined the
subcellular localization of EGFR in HT29-cav1 cells after treatment
withUDCA.We performed immunoﬂuorescent confocalmicroscopy to
visualize the localization of EGFR in the cell after treatment with EGF
and UDCA (Fig. 3A). In control cells the receptor can be seen
concentrated primarily on the cell surface and as expected treatment
of the cells with EGF resulted in internalization of EGFR and
accumulation of the receptor in perinuclear vesicles. Importantly,
UDCA led to a similar accumulation of EGFR in perinuclear vesicles
suggesting that UDCA could also induce internalization of the receptor.
To conﬁrm that EGFR was indeed lost from the cell surface we
biotinylated surface proteins and tested for this modiﬁcation of the
EGFR in the treated cells (Fig. 3B). As expected EGFR was extensively
biotinylated in control cells. However, biotinylation was reduced in
both UDCA and EGF-treated cells consistent with internalization of the
receptor. We also examined biotin-labeled EGFR on DCA-treated cells
and found that it had no measurable change in this assay.
Since caveolin-1 can suppress receptor signaling and caveolin-1
enhanced UDCA's ability to suppress mitogenic signaling we sought to
determine whether treatment with UDCA led to an association
between EGFR and caveolin-1. HT29-cav-1 cells were incubated with
DCA and UDCA and EGFR immunoprecipitated from the treated cells
Fig. 5. UDCA treatment induces association of Cbl with EGFR in the raft fraction on sucrose gradients. HT29 (A) or HT29-cav-1 (B) cells were serum-starved and incubated with IPTG
as previously described. The cells were either untreated (CTR) or incubated with 100 ng/ml EGF for 15 min (EGF), 250 μM UDCA (UDCA) or 250 μM DCA (DCA) for 18 h. Treatments
are indicated on the left of each panel. Total cell extracts were prepared and the membranes fractionated on sucrose gradients as described in Materials and methods. Aliquots of the
collected fractions were separated on SDS-PAGE gels and probed for the presence of ﬂotillin (FLO), caveolin-1 (CAV), or EGFR (EGFR), or c-Cbl (CBL) using the appropriate antibody.
The antibody used is indicated to the right of each row in each panel. The fraction numbers are marked at the top of panels A and B. Fractions from the top of the gradient on the left
(top). Fractions from the bottom of the gradient are on the right (bottom). The range of fractions that contain lipid rafts is marked at the bottom of each panel. The experiment was
repeated three times. Typical results are shown. (C) EGFR-containing fractions from the gradients in panels A (HT29) and B (HT29-cav-1) that were either untreated (CTR), treated
with UDCA (UDCA), or treated with DCA (DCA) were pooled and EGFR immunoprecipitated using an anti-EGFR antibody. The recovered proteins were separated on SDS-PAGE gels
and probedwith an anti-ubiquitin antibody and anti-EGFR antibody (upper set of gel bands). The total quantity of EGFR in these fractions was also determined by immunoblotting for
EGFR (lower set of gel bands). The experiment was repeated twice. Typical results are shown.
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noprecipitates with EGFR even in the untreated control cells, but this
increases in cells that were incubated with UDCA. Hence, there is a
physical interaction between EGFR and caveolin-1 and this is
enhanced by UDCA. In contrast, the interaction between EGFR and
caveolin-1 is suppressed by DCA. Hence, these two bile acids act in an
opposing manner.
Endocytic vesicles containing activated receptors are sorted and
the receptors they contain either degraded or recycled back to the
surface [26]. Receptors destined for degradation are ubiquitinated and
the vesicles they reside in become associated with proteins that are
characteristic of late endosomes. To determine whether UDCA could
induce endocytosis of EGFR and examine the nature of the EGFR-
containing endocytic vesicles we conducted immunoﬂuorescent
microscopy and stained for EGFR and the mannose-6-phosphate
receptor (M6P) which is a marker for late endosomes [27]. In control
cells the receptor can be seen to reside on the cell's surface and the
M6P receptor does not overlap with the EGF receptor in the mergedphotomicrographs (Fig. 4). However, in cells treated with UDCA the
EGFR accumulated in perinuclear vesicles as seen in Fig. 3A and these
also stained for the MP6 receptor. Moreover, there appeared to be a
qualitative increase in dual labeled perinuclear vesicles in UDCA-
treated HT29-cav1 cells verses HT29 parental cells. Interestingly
although we saw internalization of EGFR in DCA-treated cells there
was no colocalization of EGFR and MP6 Receptor suggesting that the
EGFR-containing vesicles were not late endosomes. Collectively our
data suggested that UDCA caused EGFR endocytosis and formation of
late endosomes.
3.3. UDCA-induced degradation of EGFR is mediated through c-Cbl
Internalization and degradation of EGFR require ubiquitination
that occurs through the actions of the c-Cbl E3 ligase [23,28].
Ubiquitination of the receptor marks the protein for degradation
and plays an important role in sorting the receptor-containing vesicles
into the late endosome pathway that leads to receptor degradation
Table 1
Comparison of EGFR half life (h) in HT29, HT29-Cav1, or HT29-cav1 cells stably
transfected with the C381A dominant negative c-Cbl mutant and treated with UDCA
or DCA.
CTR UDCA DCA
HT29 6+/−1.2 4+/−0.7 7+/−0.8
HT29-CAV1 5+/−0.5 1+/−1 0.4 8+/−1.6
C381A-2 5+/−0.7 4+/−0.4 6+/−0.1
C381A-3 6+/−1.2 6+/−1.3 5+/−0.9
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was stimulated in UDCA-treated cells. To explore this we fractionated
DCA- and UDCA-treated HT29 and HT29-cav-1 cell lysates on sucrose
gradients (Fig. 5A and B). Fractions from the gradients were probed for
a variety of markers including ﬂotillin and caveolin-1 which identify
lipid rafts and caveolae. When we probed the fractions for c-Cbl we
found that c-Cbl cofractionated with EGFR in the lipid raft fractions in
both HT29 and HT29-cav1 cells treated with either EGF or UDCA.
Notably c-Cbl was absent from these fractions in control cells and in
DCA-treated cells suggesting that UDCA, but not DCA, caused c-Cbl to
be recruited to lipid rafts in the plasma membrane. To further
investigate the fate of EGFR in UDCA-treated cells we pooled the
EGFR-containing fractions from sucrose gradients for control and bile
acid-treated cells and immunoprecipitated the receptor. The immu-
noprecipitated proteins were probed for the presence of ubiquitin by
immunoblotting which showed no ubiquitination in the control or in
DCA-treated cells (Fig. 5C). However, EGFR was extensively ubiquiti-
nated in UDCA-treated cells. Moreover, the extent of ubiquitination
was enhanced in HT29-cav-1 cells as compared to parental HT29 cells
suggesting that ubiquitination of EGFR was favored in the presence of
caveolin-1. Hence, UDCA, but not DCA, caused recruitment of c-Cbl to
EGFR which subsequently led to ubiquitination of the receptor.
Our experiments implicated c-Cbl as having an important role in
the biological effects manifested by UDCA. To test this we inactivated
c-Cbl genetically using a dominant negative mutant. HT29-cav-1 cells
were stably transfected with the pcDNA3-HA-c-cbl vector and an
empty vector. Seven clones were successfully expanded and tested by
immunoblotting for the presence of the pcDCA3-HA-c-Cbl which
could be distinguished from endogenous c-Cbl by virtue of the HA tag
(Fig. 6A). Of the clones that were established we chose to furtherFig. 6. Dominant negative c-Cbl inhibits UDCA-induced growth suppression. (A) The
pcDNA3-HA-C381A-c-Cbl which drives expression of a dominant negative HA-tagged c-
Cbl was stably introduced into HT29-cav-1 cells. Seven clones were examined for the
presence of C381A (0 through 6), by immunoblotting for total c-Cbl (top row) using an
anti-Cbl antibody or the dominant negative protein using an anti-HA antibody. (B) HT29
cells (control) and dominant negative expressing C381A-2 (C381A_2) and C381A-3
(CD81A_3) cellswere platedonto 60mmplates andeither left untreatedor incubatedwith
250 μM UDCA (+UDCA). Cells were trypsinized from the plates at regular intervals and
counted. The experiment was performed in triplicate. The average values are graphed.characterize clones C381A_2 and C381A_3 since they expressed the
highest levels of the HA-tagged c-Cbl. To determine if loss of c-Cbl
function affected UDCA-induced growth suppression, we examined
the growth of these cells in the presence of UDCA. As expected, growth
of the HT29 control cells was suppressed (Fig. 6B). However, we found
no signiﬁcant suppression of growth by UDCA in of any of the cells
expressing a dominant negative c-Cbl when compared with untreated
control cells. Hence, UDCA's ability to suppress the growth of cells
with a nonfunctional c-Cbl was eliminated which suggested that c-Cbl
plays an important role in UDCA-induced growth suppression.
Thus far our data implied that UDCA promoted conditions that
should favor degradation of EGFR. To directly test this we examined
the half lives of the receptor in parental HT29, HT29-cav-1 cells and in
the C381A_2 and C381A_3 cell lines using the pulse-chase method.
Results are shown in Table 1. The EGFR half life in untreated HT29 cells
was determined to be about 6 h and this remained unchanged in the
untreated HT29-cav-1 caveolin-1 expressing cells. Treatment with
UDCA caused a 30% reduction in the half life of EGFR in parental HT29
cells and a ﬁve fold decrease in receptor half life in the HT29-cav-1
cells when compared to the untreated controls. Hence, the EGFR half
life was signiﬁcantly shortened in cells expressing caveolin-1 and
treatedwith UDCA indicating that under these conditions degradation
of the receptor was markedly increased. In contrast, DCA treatment
had no effect on the half life of EGFR and when we examined the half
life in the C381A_2 and C381A_3 cells, we found that it was similar to
the untreated controls. These results conﬁrm the essential role of c-Cbl
in promoting receptor degradation by UDCA and suggest that receptor
degradation is a key outcome of exposure to UDCA.
4. Discussion
Our studies suggest that the bile acid, UDCA, which shows
chemoprevention activity in clinical trials, acts through a novel
mechanism to down regulate mitogenic signaling. UDCA can
suppress cell proliferation and our data showed that this effect was
potentiated by caveolin-1. Suppression of ERK MAP kinase activity by
UDCA was also enhanced by caveolin-1 suggesting that caveolin-1
augmented UDCA's ability to suppress cell proliferation through the
inhibition of mitogenic signaling. This is consistent with caveolin-1's
role as a suppressor of receptor-mediated MAP kinase signaling
[24,29]. Caveolae, the membrane structures containing caveolin-1,
are known to suppress receptor activity when receptors are recruited
into these structures [30] and our data demonstrating that there is an
enhanced physical interaction between caveolin-1 and EGFR implies
that a key effect of UDCA is to promote the down regulation of
transmembrane receptor activity. This is supported by our ﬁnding
that UDCA's growth suppressing capacity is reduced in cells that lack
caveolin-1. It should be noted, however, that UDCA does not act
exclusively through caveolin-1 since UDCA was still capable of
modest growth suppression of cells that lack caveolin-1. Hence, it is
possible that UDCA may inﬂuence the functioning of other
membrane structures such as clathrin coated pits which are also
known to play an important role in the processing of receptors such
as EGFR [31]. In any case, UDCA's affects at the plasma membrane
appear to play an important role in the biological activity exhibited
by this bile acid.
Fig. 7. Model of UDCA-induced down regulation of EGFR.
1393R. Feldman, J.D. Martinez / Biochimica et Biophysica Acta 1793 (2009) 1387–1394A key event in the down regulation of EGFR and other receptors
that collect in caveolae is the internalization of the receptor.
Concordantly, we showed that EGFR became internalized and
collected in late endosomal vesicles that fuse with lysosomes which
results in receptor degradation [31]. Ubiquitination acts as a marker
that targets receptors to a degradative pathway [26,28,32] and when
we examined EGFRwe found that it became ubiquitinated in response
to UDCA treatment. This was accompanied by a reduced half life for
the receptor indicating that UDCA promoted more rapid receptor
turnover. c-Cbl is an E3 ubiquitin ligase that promotes degradation of
some receptors by tagging with ubiquitin [33]. Importantly, decreased
receptor stability in UDCA-treated cells was accompanied by the
appearance of c-Cbl in the same sucrose gradient fractions as EGFR
and caveolin-1 suggesting that c-Cbl plays an important role in the
degradation of EGFR that is promoted by UDCA. We conﬁrmed the
importance of c-Cbl for UDCA's effect on cells by suppressing c-Cbl
activity with a dominant negative protein which reduced UDCA-
enhanced degradation of EGFR and reduced UDCA's ability to suppress
cell proliferation. Hence, UDCA's anti-proliferative effect on cells is a
consequence of its ability to augment normal receptor processing [34].
A model showing how UDCA may promote silencing of EGFR is
depicted in Fig. 7.
In contrast our studies indicate that the effects of DCA on the EGFR
are markedly different from that seen with UDCA. Cells treated with
DCA showed no ubiquitination of EGFR and no recruitment of c-Cbl to
the membrane. Yet, the EGF receptor did appear to be internalized in
response to DCA. With regard to this it is notable that the endosomes
in DCA-treated cells were not late endosomes (did not stain for the
mannose-6 phosphate receptor) suggesting that EGFR-containing
endosomes do not favor degradation of the receptor. This is consistent
with our observation that the half life of the receptor was not altered
in these cells.
So what is the fate of EGFR in DCA-treated cells? One possibility is
that the receptor may be recycled back to the surface or may continue
to signal from endocytic vesicles. It has been shown that EGFR can
follow two routes once internalized, it can either be degraded or it canbe recycled back to the surface where it can continue to signal [35].
This possibility is suggested by two seemingly contradictory results,
onewhich shows that there is no change in the surface biotinylation of
EGFR in DCA-treated cells (Fig. 3B) and the other that EGFR is
apparently internalized (Fig. 3A). Recycling EGFR back to the cell
surface would counteract loss of the receptor from the plasma
membrane and so the quantity of the protein at the surface would
seem to remain unchanged in the biotinylation experiment. Experi-
ments to directly test this are currently in progress in our laboratory.
It is unclear how DCA could promote a different route for
processing of EGFR. One possibility is that DCA activates a different
endocytic pathway. Our results are consistent with this in that DCA
causes a reduction in the association between EGFR and caveolin-1
and DCA does not promote recruitment of c-Cbl to lipid rafts as does
UDCA. Hence, receptor internalization induced by DCA appears not to
require caveolin-1 although caveolin-1 does inﬂuence activity of this
bile acid. We previously showed that down regulation of MAP kinase
activity by UDCA can suppress DCA-induced apoptosis [16]. Since
caveolin-1 suppresses MAP kinase signaling [24] it seems likely that
the reduced DCA-induced apoptosis observed in HT29-cav-1 cells is
due to reduced MAP kinase signaling. In spite of these differences in
signaling activity it seems apparent that there is considerable overlap
between UDCA and DCA in processing of receptors. This is consistent
with genetic studies which also suggest that there is overlap in the
cellular components that are activated by both bile acids even though
the biological outcome that results from exposure to each of these
agents is distinctly different [36]. Hence, the functional distinction
between a tumor promoting bile acid and a chemopreventing bile acid
may ultimately be determined by how receptors are processed once
they are internalized.
Interestingly, others have suggested similar mechanism of action
for (−)-Epigallocatechin Gallate (EGCG), the biologically active
ingredient in green tea. Weinstein et al. report that EGCG promotes
the down regulation of EGFR by altering membrane organization
leading to inhibition of EGFR activation [37]. In addition, the presence
of caveolin-1 down regulates inducible nitric oxide synthase by
reducing iNOS protein levels through accelerated degradation via the
proteasome pathway [38]. These observations in conjunctionwith our
ﬁndings suggest that augmentation of receptor processing through the
manipulation of the plasmamembrane to suppress receptor-mediated
mitogenic signaling may be a useful in the design of chemopreventive
strategies.
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